Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2009-12-22
2010-06-15
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07736861
ABSTRACT:
A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.
REFERENCES:
patent: 2007/0264193 (2007-11-01), Shojaei et al.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Hamada et al (Anticancer Research, 2002, 22:4281-4284).
Shidham et al (The American Journal of Surgical Pathology, 2001, 25(8): 1039-1049).
Hamada et al., “Clinical Effects of Tumor-associated Macrophages and Dendritic Cells on Renal Cell Carcinoma,”Anticancer Research, vol. 22, pp. 4281-4284, 2002.
Kobayashi et al., “Tumor Infiltrating Dendritic Cells Predict Treatment Response to Immmunotherapy [sic] in Patients with Metastatic Renal Cell Carcinoma,”Anticancer Research, vol. 27, pp. 1137-1141, 2007.
Murdoch et al., “The Role of Myeloid Cells in the Promotion of Tumour Angiogenesis,”Nature Reviews / Cancer, Aug. 2008, vol. 8, pp. 618-631.
Shojaei et al., “G-CSF-initiated Myeloid Cell Mobilization and Angiogenesis Mediate Tumor Refractoriness to Anti-VEGF Therapy in Mouse Models,”PNAS, Apr. 21, 2009, vol. 106, No. 16, pp. 6742-6747.
Shojaei et al., “Tumor Refractoriness to Anti-VEGF Treatment is Mediated by CD11b+Gr1+Myeloid Cells,”Nature Biotechnology, vol. 25, No. 8, Aug. 2007, pp. 911-920.
Feng Bin
Jiang Feng
Lin Jie
Robinson Murray
Sun Xiaojian
Aeder Sean E
AVEO Pharmaceuticals, Inc.
Creason Gary L.
LandOfFree
Tivozanib response prediction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tivozanib response prediction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tivozanib response prediction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189293